

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **ANNOUNCEMENT**

### **POLL RESULTS OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 22 AUGUST 2022**

References are made to the notice of 2022 first extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 2 August 2022. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

#### **POLL RESULTS OF THE EGM**

The EGM was held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC on Monday, 22 August 2022. The EGM was convened lawfully and validly in accordance with the Company Law and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

As at the date of the EGM, the total number of issued Shares of the Company was 879,967,700 Shares (comprising a total of 226,200,000 issued Domestic Shares and a total of 653,767,700 issued H Shares), entitling the holders thereof to attend the EGM and vote for or against or abstain from voting on the resolutions proposed at the EGM (saved as stated below).

Shareholders attending the EGM, either in person or by proxy, held an aggregate of 113,267,751 Shares with voting rights, representing approximately 12.871808% of the total number of the issued Shares.

Sunshine Lake Pharma Co., Ltd.\* (廣東東陽光藥業有限公司) (holding 226,200,000 Domestic Shares as at the date of the EGM), HEC (Hong Kong) Sales Co., Limited (holding 226,200,000 H Shares as at the date of the EGM) and Guangdong HEC Technology Holding Co., Ltd.\* (廣東東陽光科技控股股份有限公司) (holding 21,815,200 H Shares as at the date of the EGM) are deemed to have a material interest in the Continuing Connected Transaction Agreements entered into between the Company and Shenzhen HEC Industrial, and are required to abstain from voting on the resolutions in respect of the Continuing Connected Transaction Agreements and their respective proposed annual cap. Save as disclosed in this announcement, no Shareholder was required by the Listing Rules to abstain from voting on any of the resolutions proposed at the EGM. Therefore, an aggregate of 405,752,500 Shares (representing approximately 46.11% of the total number of the issued Shares of the Company) entitle the Independent Shareholders to attend the EGM and vote on the resolutions.

Saved as disclosed above, there was no Share entitling its holder to attend the EGM and abstain from voting in favour of any of the proposed resolutions under Rule 13.40 of the Listing Rules and no Shareholder has stated the intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions. All the proposed resolutions were voted by way of poll. Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for vote-taking at the EGM. Two shareholder representatives and one supervisor of the Company also acted as the scrutineers for the vote-taking and vote-tabulation.

All Directors attended the EGM.

### Poll Results of the EGM

The poll results of the EGM are as follows:

ORDINARY RESOLUTIONS		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)
1.	THAT (a) the execution of the Energy Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Energy Purchase Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%

ORDINARY RESOLUTIONS		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)
2.	<b>THAT</b> (a) the execution of the APIs Purchase Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the APIs Purchase Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%
3.	<b>THAT</b> (a) the execution of the Packaging and Production Materials Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Packaging and Production Materials Purchase Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%
4.	<b>THAT</b> (a) the execution of the Equipment Purchase and Civil Construction Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Purchase and Civil Construction Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%
5.	<b>THAT</b> (a) the execution of the Entrusted Processing Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Processing Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%

ORDINARY RESOLUTIONS		FOR		AGAINST		ABSTAIN	
		NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)	NUMBER OF VOTES	PERCENTAGE OF TOTAL NUMBER OF VOTES (%)
6.	<b>THAT</b> (a) the execution of the Leasing and Other Services Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Leasing and Other Services Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%
7.	<b>THAT</b> (a) the execution of the APIs and Pharmaceutical Products Sales Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the APIs and Pharmaceutical Products Sales Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%
8.	<b>THAT</b> (a) the execution of the Entrusted Production and Inspection Services Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Production and Inspection Services Framework Agreement and the proposed annual cap for the year ending 31 December 2022 as set out in the Circular be and are hereby approved.	113,267,751	100.000000%	0	0.000000%	0	0.000000%

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 1 to 8, these resolutions were duly passed as ordinary resolutions.

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfa**  
*Chairman*

Hubei, the PRC  
22 August 2022

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yanguai and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*

\* *For identification purpose only*